Glucagon-like peptide 1 receptor plays a critical role in geniposide-regulated insulin secretion in INS-1 cells

Acta Pharmacologica Sinica

Volumn 33, Issue 2, 2012, Pages 237-241

  Guo, Li Xia ^a,b   Xia, Zhi Ning ^a   Xue, Gao ^b   Fei, Yin ^b   Liu, Jian Hui ^b  

^a CHONGQING UNIVERSITY   (China)

^b CHONGQING TECHNOLOGY AND BUSINESS UNIVERSITY   (China)

Author keywords

Geniposide; glucagon like peptide 1 receptor; insulin secretion; RNA interference; type 2 diabetes mellitus

Indexed keywords

EXENDIN 4; GENIPOSIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INSULIN; SHORT HAIRPIN RNA;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ARTICLE; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE SILENCING; HORMONE DETERMINATION; INSULIN RELEASE; INSULINOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT; WESTERN BLOTTING;

ANIMALS; CELL LINE, TUMOR; DIABETES MELLITUS, TYPE 2; GARDENIA; GLUCAGON-LIKE PEPTIDE 1; INSULIN; IRIDOIDS; ISLETS OF LANGERHANS; PLANT EXTRACTS; RATS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84863133805     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2011.146     Document Type: Article

References (20)

1. Bergsten P. Pathophysiology of impaired pulsatile insulin release. Diabetes Metab Res Rev 2000; 16: 179-91. (Pubitemid 30410274)
2. Kano Y, Kanatsuna T, Nakamura N, Kitagawa Y, Mori H, Kajiyama S, et al. Defect of the frst-phase insulin secretion to glucose stimulation in the perfused pancreas of the nonobese diabetic (NOD) mouse. Diabetes 1986; 35: 486-90. (Pubitemid 16078464)
3. Hartter E, Svoboda T, Ludvik B, Schuller M, Lell B, Kuenburg E, et al. Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans. Diabetologia 1991; 34: 52-4.
4. Guillausseau PJ, Meas T, Virally M, Laloi-Michelin M, Medeau V, Kevorkian JP. Abnormalities in insulin secretion in type 2 diabetes mellitus. Diabetes Metab 2008; 34 Suppl 2: S43-8. (Pubitemid 351982036)
5. Arulmozhi DK, Portha B. GLP-1 based therapy for type 2 diabetes. Eur J Pharm Sci 2006; 28: 96-108.
6. Kielgast U, Holst J, Madsbad S. Treatment of type 1 diabetic patients with glucagon-like peptide-1 (GLP-1) and GLP-1R agonists. Curr Diabetes Rev 2009; 5: 266-75.
7. Egan JM, Bulotta A, Hui H, Perfetti R. GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells. Diabetes Metab Res Rev 2003; 19: 115-23. (Pubitemid 36417195)
8. Cornu M, Thorens B. GLP-1 protects beta-cells against apoptosis by enhancing the activity of an IGF-2/IGF1-receptor autocrine loop. Islets 2009; 1: 280-2.
9. Ahren B, Winzell MS, Wierup N, Sundler F, Burkey B, Hughes TE. DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with beta-cell-specific overexpression of human islet amyloid polypeptide. Regul Pept 2007; 143: 97-103. (Pubitemid 47212530)
10. Liu JH, Zheng XX, Yin F, Hu YH, Guo LX, Deng X, et al. Neurotrophic property of geniposide for inducing the neuronal differentiation of PC12 cells. Int J Dev Neurosci 2006; 24: 419-24. (Pubitemid 44584607)
11. Yin F, Liu JH, Zheng XX, Guo LX. GLP-1 receptor plays a critical role in geniposide-induced expression of heme oxygenase-1 in PC12 cells. Acta Pharmacol Sin 2010; 31: 540-5.
12. Liu JH, Yin F, Zheng XX, Jing JJ, Hu YH. Geniposide, a novel agonist for GLP-1 receptor, prevents PC12 cells from oxidative damage via MAP kinase pathway. Neurochem Int 2007; 51: 361-9. (Pubitemid 47503463)
13. Martin S, Kolb H, Beuth J, van Leendert R, Schneider B, Scherbaum WA. Change in patients' body weight after 12 months of treatment with glimepiride or glibenclamide in type 2 diabetes: a multicentre retrospective cohort study. Diabetologia 2003; 46: 1611-7. (Pubitemid 38005323)
14. Jennings AM, Wilson RM, Ward JD. Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents. Diabetes Care 1989; 12: 203-8. (Pubitemid 19071489)
15. Jin L, Xue HY, Jin LJ, Li SY, Xu YP. Antioxidant and pancreas-protective effect of aucubin on rats with streptozotocin-induced diabetes. Eur J Pharmacol 2008; 582: 162-7.
16. Marguet D, Baggio L, Kobayashi T, Bernard AM, Pierres M, Nielsen PF, et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci U S A 2000; 97: 6874-9. (Pubitemid 30412807)
17. Verspohl EJ. Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther 2009; 124: 113-38.
18. Davies MJ, Rayman G, Grenfell A, Gray IP, Day JL, Hales CN. Loss of the first phase insulin response to intravenous glucose in subjects with persistent impaired glucose tolerance. Diabet Med 1994; 11: 432-6. (Pubitemid 24210260)
19. Del Prato S, Marchetti P, Bonadonna RC. Phasic insulin release and metabolic regulation in type 2 diabetes. Diabetes 2002; 51: S109-16. (Pubitemid 34761504)
20. Widen EI, Eriksson JG, Ekstrand AV, Groop LC. The relationship between frst-phase insulin secretion and glucose metabolism. Acta Endocrinol (Copenh) 1992; 127: 289-93.